Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
75 hedge funds and large institutions have $384M invested in Alder Biopharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 3 closing their positions.
600% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 3
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
135% more capital invested
Capital invested by funds: $163M → $384M (+$220M)
32% more funds holding
Funds holding: 57 → 75 (+18)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.2M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.08M |
| 3 |
Goldman Sachs
New York
|
+$3.81M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.79M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.17M |
| 3 |
PC
PointState Capital
New York
|
-$3.59M |
| 4 |
CCM
Cadian Capital Management
New York
|
-$1.52M |
| 5 |
Jennison Associates
New York
|
-$1.4M |
ALDR Hedge Fund Activity: Q4 2014 in Review
75 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2014, worth a combined $384M — up 135% from $163M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ALDR positions and 3 closed out — a net gain of 18 holders — while 22 added to existing stakes and 25 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $7.2M. The largest seller was PFM Health Sciences, cutting an estimated $12.6M.
- 75 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2014, up from 57 in Q3 2014.
- Funds reported $384M of Alder Biopharmaceuticals stock for Q4 2014, up 135% quarter-over-quarter.
- 21 funds opened new Alder Biopharmaceuticals positions in Q4 2014 and 3 closed out, a net change of +18 holders.
- The largest Alder Biopharmaceuticals buyer in Q4 2014 was Citadel Advisors, an estimated $7.2M added.
- The largest Alder Biopharmaceuticals seller in Q4 2014 was PFM Health Sciences, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2014.